Aridis Pharmaceuticals (NASDAQ:ARDS) Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Aridis Pharmaceuticals (NASDAQ:ARDS) from a hold rating to a sell rating in a research note issued to investors on Monday morning, Zacks.com reports.

According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company’s product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. “

Several other research analysts have also recently weighed in on ARDS. Laidlaw set a $15.00 target price on Aridis Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, September 4th. Northland Securities restated a buy rating and set a $22.00 target price on shares of Aridis Pharmaceuticals in a report on Thursday, November 14th. ValuEngine upgraded Aridis Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, Maxim Group set a $25.00 target price on Aridis Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $19.80.

Shares of Aridis Pharmaceuticals stock traded up $0.32 on Monday, hitting $5.14. 80 shares of the company were exchanged, compared to its average volume of 4,421. The stock has a market capitalization of $40.55 million, a price-to-earnings ratio of -0.73 and a beta of -0.90. The company has a 50-day moving average price of $5.78 and a 200 day moving average price of $8.41. Aridis Pharmaceuticals has a 1-year low of $4.39 and a 1-year high of $12.45.

Aridis Pharmaceuticals (NASDAQ:ARDS) last issued its earnings results on Wednesday, November 13th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.54). Aridis Pharmaceuticals had a negative return on equity of 182.31% and a negative net margin of 660.52%. As a group, sell-side analysts predict that Aridis Pharmaceuticals will post -3.79 earnings per share for the current fiscal year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Featured Article: Quick Ratio

Get a free copy of the Zacks research report on Aridis Pharmaceuticals (ARDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.